| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0755-4982(04)98888-4 |
| P698 | PubMed publication ID | 15523290 |
| P50 | author | Loïc Guillevin | Q88410079 |
| P2093 | author name string | Luc Mouthon | |
| Philippe Guilpain | |||
| Claire Larroche | |||
| Srini V Kaveri | |||
| Michel D Kazatchkine | |||
| Mathieu C Tamby | |||
| Youri Chanseaud | |||
| P2860 | cites work | The B cell superantigen-like interaction of intravenous immunoglobin (IVIG) with Fab fragments of V(H) 3-23 and 3-30/3-30.5 germline gene origin cloned from a patient with Kawasaki disease is enhanced after IVIG therapy | Q30662649 |
| Toxic epidermal necrolysis in acquired immunodeficiency syndrome treated with intravenous gammaglobulin | Q30752612 | ||
| Restricted VH3 gene usage in phage-displayed Fab that are selected by intravenous immunoglobulin | Q30977796 | ||
| Autoantibody level modification in adult patients with idiopathic thrombocytopenic purpura following intravenous immunoglobulin treatment | Q33334947 | ||
| Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor | Q33335777 | ||
| Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease | Q33347581 | ||
| Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody | Q33444635 | ||
| High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood | Q33475647 | ||
| Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin | Q33481729 | ||
| Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. | Q33492203 | ||
| Intravenous immunoglobulin treatment in cytopenic haematological disorders | Q33493736 | ||
| Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study | Q33590410 | ||
| Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion | Q34124893 | ||
| High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments | Q34155637 | ||
| Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies | Q34244201 | ||
| Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin | Q34362734 | ||
| Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. | Q34475335 | ||
| Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients | Q34521023 | ||
| Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model | Q34581633 | ||
| Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies | Q34593855 | ||
| A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis | Q34728752 | ||
| Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis | Q35566304 | ||
| Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis | Q72782818 | ||
| Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients | Q72892032 | ||
| Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group | Q73126318 | ||
| Posttranscriptional regulation of T-cell IL-2 production by human pooled immunoglobin | Q73162652 | ||
| Polyclonal immunoglobulins (IVIg) modulate nitric oxide production and microglial functions in vitro via Fc receptors | Q73276229 | ||
| A comparative study of the in vitro immunomodulatory activity of human intact immunoglobulin (7S IVIG), F(ab')2 fragments (5S IVIG) and Fc fragments. Evidence for post-transcriptional IL-2 modulation | Q73307197 | ||
| Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1alpha and interferon-alpha but not other cytokines in human immunoglobulin preparations | Q73395802 | ||
| Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure | Q73513244 | ||
| Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy | Q73550695 | ||
| Intravenous immunoglobulins in infectious diseases: where do we stand? | Q73630907 | ||
| Serum levels of neutrophil activation cytokines in Kawasaki disease | Q73707161 | ||
| Identification of an Fc gamma receptor-independent mechanism by which intravenous immunoglobulin ameliorates antiphospholipid antibody-induced thrombogenic phenotype | Q73792167 | ||
| Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity | Q73939175 | ||
| Differential inhibitory effects of intravenous immunoglobulin preparations on HLA-alloantibodies in vitro | Q73968479 | ||
| Intravenous immunoglobulin (IVIG) attenuates antibody binding in acute haemorrhagic immunopneumonitis in a rat model of complement-dependent lung injury | Q73968578 | ||
| A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis | Q74009730 | ||
| [Toxic epidermal necrolysis treated with intravenous immunoglobulins] | Q74010697 | ||
| Effect of whole and fractionated intravenous immunoglobulin on complement in vitro | Q74045510 | ||
| Intravenous immunoglobulin therapy induces neutrophil apoptosis in Kawasaki disease | Q74164064 | ||
| Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure--modulatory effect of intravenous immunoglobulin | Q74194624 | ||
| Pemphigus vulgaris: the role of IL-1 and IL-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production | Q74243220 | ||
| IVIG adverse reactions: potential role of cytokines and vasoactive substances | Q74311922 | ||
| Treatment of drug-induced toxic epidermal necrolysis (Lyell's syndrome) with intravenous human immunoglobulins | Q74432051 | ||
| Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome | Q74448171 | ||
| The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice | Q74455262 | ||
| Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis | Q74575031 | ||
| The effect of intravenous immunoglobulins on intimal thickening in a mouse model of arterial injury | Q77104415 | ||
| Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells | Q77291206 | ||
| Pooled human immunoglobulin inhibits IL-4 but not IFN-gamma or TNF-alpha secretion following in vitro stimulation of mononuclear cells with Staphylococcal superantigen | Q77753118 | ||
| Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases | Q77814999 | ||
| High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases | Q77828715 | ||
| I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome | Q77890217 | ||
| Administration of intravenous immunoglobulin (IVIG) in vivo--down-regulatory effects on the IL-1 system | Q77953405 | ||
| Intravenous immunoglobulins induce the in vitro differentiation of human B lymphocytes and the secretion of IgG | Q78654750 | ||
| Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases | Q78810942 | ||
| Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience | Q78810947 | ||
| Successful response to intravenous immunoglobulin in autoimmune haemolytic anaemia | Q93569045 | ||
| Inhibition of Complement-Mediated Red Cell Lysis by Immunoglobulins is Dependent on the IG Isotype and its Cl Binding Properties | Q63728170 | ||
| Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus | Q64387706 | ||
| Brain receptors for steroids | Q67558883 | ||
| Intravenous gamma globulin therapy in systemic juvenile rheumatoid arthritis | Q67664031 | ||
| Normal serum immunoglobulins influence the numbers of bone marrow pre-B and B cells | Q67899601 | ||
| A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group | Q68081121 | ||
| Stimulation of B and T cells by in vivo high dose immunoglobulin administration in normal mice | Q68313993 | ||
| Plasma C3c changes in myasthenia gravis patients receiving high-dose intravenous immunoglobulin during crisis | Q69800365 | ||
| An open-label study of high-dose intravenous immunoglobulin in severe childhood asthma | Q70147096 | ||
| Use of intravenous gamma globulin for the treatment of autoimmune neutropenia of childhood and autoimmune hemolytic anemia | Q70365243 | ||
| Complement interaction with immune serum globulin and immune globulin intravenous | Q70473503 | ||
| Inhibition of immunoglobulin production in vitro by IgG and F(ab')2 fragments, but not by the Fc portion | Q71084701 | ||
| Effects of immunoglobulin and gamma-interferon on the production of tumour necrosis factor-alpha and interleukin-1 beta by peripheral blood monocytes in the acute phase of Kawasaki disease | Q71457988 | ||
| Blockade of proliferation and tumor necrosis factor-alpha production occurring during mixed lymphocyte reaction by interferon-gamma-specific natural antibodies contained in intravenous immunoglobulins | Q71809482 | ||
| A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy | Q71817931 | ||
| Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations | Q72213706 | ||
| Immunologically active proteins in intravenous immunoglobulin | Q72230293 | ||
| Lymphokine production induced by streptococcal pyrogenic exotoxin-A is selectively down-regulated by pooled human IgG | Q72345231 | ||
| Inhibition of complement activation by intravenous immunoglobulins | Q72402065 | ||
| Selection of the expressed B cell repertoire by infusion of normal immunoglobulin G in a patient with autoimmune thyroiditis | Q72564618 | ||
| Intravenous immunoglobulin induces interferon-gamma and interleukin-6 in vivo | Q72619775 | ||
| Suppressive effect of intravenous immunoglobulins on the activity of interleukin-1 | Q72646657 | ||
| Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: a possible mechanism of action in vascular diseases | Q35753525 | ||
| Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis | Q35805634 | ||
| Reversible and irreversible loss of Fc receptor function of human monocytes as a consequence of interaction with immunoglobulin G. | Q37027601 | ||
| Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. | Q37351865 | ||
| Population dynamics of natural antibodies in normal and autoimmune individuals. | Q37544248 | ||
| The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor | Q37590654 | ||
| Cytokines and autoantibodies to cytokines | Q40445967 | ||
| Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment | Q40601483 | ||
| Pooled human IgG modulates cytokine production in lymphocytes and monocytes. | Q40633366 | ||
| Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy | Q40633373 | ||
| IgG induction of IL-1 receptor antagonist production by human monocytes | Q40633377 | ||
| V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (i.v.Ig). | Q40633384 | ||
| F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins | Q40667159 | ||
| Comparison of intravenous gamma globulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice | Q40682790 | ||
| IV immunoglobulin does not reverse established weakness in MS. | Q40739519 | ||
| ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin | Q40909926 | ||
| Inhibition of IL-12 synthesis of peripheral blood mononuclear cells (PBMC) stimulated with a bacterial superantigen by pooled human immunoglobulin: implications for its effect on Kawasaki disease (KD). | Q40993956 | ||
| In vitro inhibitory activity of tumor necrosis factor alpha and interleukin-2 of human immunoglobulin preparations | Q41074178 | ||
| Intravenous immune globulin therapy for neurologic diseases | Q41461397 | ||
| Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg) | Q41552141 | ||
| On the mechanism of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy | Q41722741 | ||
| Circulating transforming growth factor beta 1 (TGF-beta1) in Guillain-Barré syndrome: decreased concentrations in the early course and increase with motor function | Q42123972 | ||
| Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis | Q43692392 | ||
| Inhibition of IgE production in vitro by intact and fragmented intravenous immunoglobulin | Q43701904 | ||
| Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience | Q43732597 | ||
| Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment | Q43801568 | ||
| Intravenous immunoglobulin (IVIG) preparations induce apoptosis in TNF-alpha-stimulated endothelial cells via a mitochondria-dependent pathway | Q43967311 | ||
| Suppression of IL-4- and CD40-induced B-lymphocyte activation by intravenous immunoglobulin is not mediated through the inhibitory IgG receptor FcgammaRIIb | Q44123869 | ||
| Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris | Q44133213 | ||
| Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression | Q44281670 | ||
| Polyreactive autoantibodies purified from human intravenous immunoglobulins prevent the development of experimental autoimmune diseases | Q44513291 | ||
| A V region-connected autoreactive subfraction of normal human serum immunoglobulin G. | Q45210042 | ||
| High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study | Q45361840 | ||
| Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin | Q46004059 | ||
| Fab fragments from intravenous immunoglobulin prevent hyperacute rejection in the guinea pig-to-rat combination without reducing hemolytic complement activity in rat serum. | Q46830748 | ||
| Targeting of IgMkappa antibodies to oligodendrocytes promotes CNS remyelination. | Q48393595 | ||
| Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses | Q48522401 | ||
| Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study | Q48954233 | ||
| Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study | Q49125609 | ||
| Differential regulation of myelin phagocytosis by macrophages/microglia, involvement of target myelin, Fc receptors and activation by intravenous immunoglobulins. | Q52959839 | ||
| Intravenous immunoglobulins and transforming growth factor beta. | Q53713091 | ||
| Effect of intravenous immunoglobulin on steroid consumption in patients with severe asthma: a double-blind, placebo-controlled, randomized trial. | Q53932125 | ||
| Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin. | Q54103259 | ||
| Gamma-globulins prepared from sera of multiparous women bind anti-HLA antibodies and inhibit an established in vivo human alloimmune response. | Q54662875 | ||
| Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin) | Q57723250 | ||
| Expression of anti-idiotypic clones against auto-anti-DNA antibodies in normal individuals | Q58003193 | ||
| Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis | Q58416378 | ||
| The Treatment of Kawasaki Syndrome with Intravenous Gamma Globulin | Q58478448 | ||
| Human polyspecific immunoglobulin for therapeutic use induces p21/WAF-1 and Bcl-2, which may be responsible for G1 arrest and long-term survival | Q58823340 | ||
| Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin | Q58864690 | ||
| Naturally occurring anti-idiotypic antibodies in myasthenia gravis patients | Q59071320 | ||
| A case of toxic epidermal necrolysis treated with intravenous immunoglobulin | Q59595384 | ||
| High-Dose Intravenous Immune Globulin for Stiff-Person Syndrome | Q59649757 | ||
| Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect | Q60649744 | ||
| P433 | issue | 17 | |
| P407 | language of work or name | French | Q150 |
| P304 | page(s) | 1183-1194 | |
| P577 | publication date | 2004-10-01 | |
| P1433 | published in | Presse médicale | Q127260618 |
| P1476 | title | [Immunomodulatory effects of intravenous immunoglobulins] | |
| P478 | volume | 33 |
| Q37052726 | Advances in the treatments of systemic vasculitides |
| Q58861264 | Indications et mécanismes d’action des immunoglobulines intraveineuses dans les pathologies auto-immunes et inflammatoires systémiques |
| Q36787732 | Indications for biotherapy in systemic vasculitides |
| Q81317771 | [Intravenous immunoglobulins: therapeutic indications] |
Search more.